Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma

Pediatric Blood and Cancer

Volumn 50, Issue 2, 2008, Pages 280-283

  Dinand, Veronique ^a   Malik, Ajay ^a   Unni, Rajani ^a   Arya, Laxman S ^b   Pandey, R M ^a   Dawar, Ramesh ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b INDRAPRASTHA APOLLO HOSPITAL   (India)

Author keywords

Apoptosis; Children; Hodgkin lymphoma; Immunophenotyping; Proliferation; Treatment outcome

Indexed keywords

BLEOMYCIN; CD15 ANTIGEN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; KI 67 ANTIGEN; PREDNISOLONE; PROCARBAZINE; PROTEIN P53; VINBLASTINE; VINCRISTINE;

ADOLESCENT; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CELL PROLIFERATION; CHILD; CLASSICAL HODGKIN LYMPHOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LYMPH NODE BIOPSY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REED STERNBERG CELL;

ADOLESCENT; ANTIGENS, CD15; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CELL GROWTH PROCESSES; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; DACARBAZINE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIERS ESTIMATE; KI-67 ANTIGEN; MALE; NEOPLASM STAGING; PREDNISONE; PROCARBAZINE; RETROSPECTIVE STUDIES; TUMOR SUPPRESSOR PROTEIN P53; VINBLASTINE; VINCRISTINE;

EID: 37549037495     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21204     Document Type: Article

References (19)

1. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J 2000; 1:53-66.
2. Schellong G, Pötter R, Brämswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999;17:3736-3744.
3. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: Response-adapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisolone before low-dose radiation therapy - Results of the French Society of Pediatric Oncology study M DH90. J Clin Oncol 2000;18:1500-1507.
4. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003;21:2026-2033.
5. von Wasielewski R, Mengel M, Fischer R, et al. Classical Hodgkin's disease. Clinical impact of the immunophenotype. Am J Pathol 1997;151:1123-1130.
6. Vassalo J, Metze K, Traina F, et al. Expression of Epstein-Barr virus in classic Hodgkin's lymphomas in Brazilian adult patients. Haematologica 2001;86:1227-1228.
7. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging. Cancer Res 1971;31:1860-1861.
8. Arya LS, Dinand V, Thavaraj V, et al. Hodgkin's disease in Indian children: Outcome with chemotherapy alone. Pediatr Blood Cancer 2006;46:26-34.
9. Dinand V, Dawar R, Arya LS, et al. Hodgkin's lymphoma in Indian children: Prevalence and significance of Epstein-Barr virus detection in Hodgkin's and Reed Sternberg cells. Eur J Cancer 2007;43:161-168.
10. Sitar G, Bianchi Santamaria A, Rosti V, et al. Giant cell formation in Hodgkin's disease. Res Immunol 1994;145:499-515.
11. Re D, Benenson E, Beyer M, et al. Cell fusion is not involved in the generation of giant cells in the Hodgkin-Reed Sternberg cell line L1236. Am J Hematol 2001;67:6-9.
12. Valeriote F, van Putten L. Proliferation-dependant cytotoxicity in anticancer agents: A review. Cancer Res 1975;35:2619-2630.
13. Abele MC, Valente G, Kerim S, et al. Significance of cell proliferation index in assessing histological prognostic categories in Hodgkin's disease. An immunohistochemical study with Ki67 and MIB-1 monoclonal antibodies. Haematologica 1997;82:281-285.
14. Wang J, Taylor CR. Apoptosis and cell-cycle related genes and proteins in classical Hodgkin's lymphoma: Application of tissue microarray technique. Appl Immunohistochem Mol Morphol 2003;11:206-213.
15. Morente MM, Piris MA, Abraira V, et al. Adverse clinical outcome in Hodgkin's disease is associated with loss of RB protein expression, high Ki67 proliferation index and absence of EBV latent membrane protein 1 expression. Blood 1997;90:2429-2436.
16. Smolewski P, Niewiadomska H, Blonski JZ, et al. Expression of proliferating cell nuclear antigen (PCNA) and p53, bcl-2 or C-erb B-2 proteins on Reed-Sternberg cells: Prognostic significance in Hodgkin's disease. Neoplasma 1998;45:140-147.
17. Claviez A, Tiemann M, Peters J, et al. The impact of EBV, proliferation rate and bcl-2 expression in Hodgkin's disease in childhood. Ann Hematol 1994;68:61-66.
18. Tiemann M, Claviez A, Luders H, et al. Proliferation characteristics in pediatric Hodgkin's lymphoma point to a cell cycle arrest in the G(1) phase. Mod Pathol 2005;18:1440-1447.
19. Naresh KN, Johnson J, Srinivas V, et al. Epstein-Barr virus association in classical Hodgkin's disease provides survival advantage to patients and correlates with higher expression of proliferation markers in Reed-Sternberg cells. Ann Oncol 2000;11: 91-96.